THYREOS, INC
Biotech · Private
Live-attenuated HSV-2 vaccine based on R2 technology platform
- Grants
- $2.0M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Agriculture · Bovine Alphaherpesvirus 1 (BOHV-1) Is Endemic In The Usa Cattle Population And Responsible For Significant Economic Loss To The Milk And Beef Industries. Although Vaccines Are Commercially Available, None Are Competent To Protect The ANIMAL'S Nervous System From BOHV-1 Invasion And The Subsequent Establishment Of Life-long Latent Infections. In Addition To Being The Source Of Infectious Bovine Rhinotracheitis (ibr), BOHV-1 Is A Causative Agent Of Shipping Fever, Which Results From Stress Pla | $174,235 | |
| Federal grant | Department of Health and Human Services · Phase II · An R2 non-neuroinvasive herpes simplex virus type 2 vaccine | $297,493 | |
| Federal grant | Department of Health and Human Services · Phase II · An R2 non-neuroinvasive herpes simplex virus type 2 vaccine | $663,123 | |
| Federal grant | Department of Health and Human Services · Phase II · An R2 non-neuroinvasive herpes simplex virus type 2 vaccine | $703,683 | |
| Federal grant | Department of Agriculture · Bovine Respiratory Disease (brd) Is The Leading Cause Of Illness, Death, And Economic Loss By Infectious Disease In The Cattle Industry, Responsible For Over A Billion Dollars In Annual Costs In The United States. Brd Is Caused By A Complex Of Viral And Bacterial Pathogens Including Bovine Herpesvirus Type 1 (BOHV-1), Bovine Respiratory Syncytial Virus (brsv), And Bovine Parainfluenza Virus (BPIV-3). Current Vaccines Offer Limited Protection And Present Safety Concerns, Particularly Because Bohv | $174,699 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2706 | Helicore Biopharma | — | — |
| 2707 | VELAKOR BIOTHERAPEUTICS, INC. | — | — |
| 2708 | Alltrna | — | — |
| 2709 | THYREOS, INC | — | — |
| 2710 | ISOPRENE PHARMACEUTICALS, INC. | — | — |
| 2711 | KATHERA BIOSCIENCE INC. | — | — |
| 2712 | ENCUE INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.